Future Medicine Decision Guide
Amycretin (Zenagamtide) UK: Definitive Future-Medicine Guide
An evidence-led UK guide to Amycretin/Zenagamtide: GLP-1 plus amylin biology, oral and injectable development, Phase 3 status, safety, comparisons and whether it is worth waiting for.
Amycretin / Zenagamtide: where it stands now
Amycretin is still investigational.
Novo Nordisk now refers to the molecule as zenagamtide (amycretin). Its 2025 annual report said the programme was advancing to initiate Phase 3 trials in 2026. It is not a routine UK prescription treatment today.
This is important because early weight-loss numbers have been eye-catching, but the treatment still needs the kind of larger and longer studies that establish practical dosing, safety, durability and comparative effectiveness.
What is Amycretin / Zenagamtide?
Amycretin is a single molecule designed to activate both GLP-1 and amylin receptors. That makes it conceptually different from CagriSema, which combines two separate active medicines — semaglutide plus cagrilintide.
GLP-1 activity
Targets appetite, fullness and glucose-dependent insulin signalling.
Amylin activity
Adds another satiety pathway associated with reduced food intake.
One molecule
The two activities are engineered into one unimolecular treatment rather than delivered as a two-drug combination.
Why combine GLP-1 and amylin?
GLP-1 and amylin both contribute to meal-related satiety but through partly different biological pathways. The theory is that combining them could create stronger appetite regulation than either pathway alone while avoiding the complexity of administering separate medicines.
The clinical question is whether that theoretical elegance actually translates into enough extra benefit, acceptable tolerability and a useful maintenance strategy.
Could Amycretin be a pill as well as an injection?
One of the most interesting features of the programme is that both oral and subcutaneous formulations have been investigated. Novo Nordisk has reported substantial weight reduction in early studies of both forms.
If an oral formulation survives Phase 3 and regulatory review, it could matter commercially because many people dislike injections. But convenience alone does not decide whether a treatment is superior — adherence, dosing rules, cost, tolerability and weight-loss durability all matter.
What has the evidence shown so far?
Published Phase 1b/2a research reported substantial body-weight reductions with weekly subcutaneous amycretin over 36 weeks, with the highest studied dose producing average weight loss in the mid-20% range in the trial analysis. Earlier oral studies also showed rapid weight reduction over shorter treatment periods.
Small and medium early-phase trials can look spectacular. Phase 3 is where we learn whether the effect is reproducible in larger, more diverse populations over longer periods.
What happens in Phase 3?
Novo Nordisk moved zenagamtide into a Phase 3 development strategy during 2026. Phase 3 matters because it is designed to establish the balance of benefit and risk at scale and create the evidence package needed for potential regulatory submissions.
Questions Phase 3 needs to answer include optimal dose, oral vs injectable positioning, long-term tolerability, weight-loss plateau, maintenance and performance in people with type 2 diabetes or other obesity-related conditions.
Side effects and uncertainty
Early studies have reported gastrointestinal effects broadly consistent with GLP-1/amylin biology, including nausea and vomiting. But it is too early to write a final “side-effect guide” because there is no UK-approved product label yet.
The correct position today is: encouraging efficacy signal, incomplete long-term safety picture.
When will Amycretin be available in the UK?
There is no confirmed UK launch date. Phase 3 development has begun, and any eventual UK treatment would still require regulatory authorisation followed by separate commercial and NHS decisions.
Do not confuse “Phase 3 started” with “available next year”. Drug development timelines can change.
Amycretin vs CagriSema
| Amycretin | CagriSema | |
|---|---|---|
| Core biology | GLP-1 + amylin | GLP-1 + amylin |
| Design | Single unimolecular agonist | Two-drug combination |
| Development | Phase 3 development beginning | Advanced Phase 3 / regulatory programme |
| Oral potential | Yes, studied | Primarily weekly injectable combination |
Amycretin vs Mounjaro
Mounjaro is an authorised GIP/GLP-1 treatment with established UK prescribing pathways. Amycretin uses GLP-1 plus amylin and remains investigational. Early efficacy numbers may look competitive, but comparing an approved medicine with an early development candidate using separate trials is not a fair head-to-head.
Amycretin vs Retatrutide
Retatrutide is a GIP/GLP-1/glucagon triple agonist with advanced Phase 3 evidence. Amycretin is a GLP-1/amylin co-agonist at an earlier stage. They represent two different attempts to move beyond GLP-1-only therapy.
Should I wait for Amycretin?
If you need treatment now, no sensible guide should tell you to delay appropriate care for an investigational medicine. If you're doing well without medication, keep going. If future Amycretin approval eventually offers a material advantage, you can reconsider then.
Questions you haven't thought to ask yet
- Will oral and injectable Amycretin deliver similar long-term results?
- Will oral dosing have food or water restrictions?
- Will the amylin component change nausea patterns?
- How will it compare directly with CagriSema?
- What maintenance dose will be needed?
- Would the convenience of a pill justify switching from a treatment already working?
Shift Says
Our take
Amycretin is genuinely interesting because it could combine two powerful satiety pathways in one molecule and potentially offer an oral route. But it is still a development programme, not a UK treatment decision today.
Watch the Phase 3 evidence. Don't buy the hype before the evidence arrives.
Printable summary
Amycretin checklist
- Investigational, not routine UK treatment.
- Single GLP-1 + amylin co-agonist.
- Oral and injectable forms are being developed.
- Phase 3 is now the important next evidence step.
- Do not delay appropriate treatment today solely to wait for it.
FAQs
Is Amycretin available in the UK?
No. It remains investigational.
Is Amycretin the same as CagriSema?
No. Both target GLP-1 and amylin biology, but Amycretin is a single molecule while CagriSema combines semaglutide with cagrilintide.
Can Amycretin be taken as a tablet?
Oral and injectable formulations have been studied.
Has Amycretin reached Phase 3?
Novo Nordisk advanced zenagamtide to initiate Phase 3 development in 2026.
How much weight did people lose?
Early subcutaneous studies reported average losses in the mid-20% range at higher studied doses, but these are not Phase 3 outcomes.
Should I wait for Amycretin?
Not if you need appropriate treatment now. Revisit it when Phase 3 and regulatory evidence are mature.
Sources & further reading
Future-medicine status changes quickly, so we prioritise regulator, manufacturer and official trial sources and date-stamp the page.
The Shift Programme is coming soon
You do not need to wait for future medicines to start making progress. Tell us how we can reach out when our programme is ready.
Register to Shift Some TimberPut it head-to-head
Want to see how this option stacks up against another future medicine — or against Mounjaro or Wegovy?
Open comparison checker